Voya Investment Management LLC purchased a new position in Adamas Pharmaceuticals Inc (NASDAQ:ADMS) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 8,666 shares of the specialty pharmaceutical company’s stock, valued at approximately $224,000.
Several other hedge funds and other institutional investors also recently made changes to their positions in ADMS. BlackRock Inc. lifted its holdings in shares of Adamas Pharmaceuticals by 24.3% in the 2nd quarter. BlackRock Inc. now owns 1,846,096 shares of the specialty pharmaceutical company’s stock worth $47,684,000 after purchasing an additional 361,303 shares during the last quarter. UBS Group AG lifted its holdings in shares of Adamas Pharmaceuticals by 399.4% in the 1st quarter. UBS Group AG now owns 194,503 shares of the specialty pharmaceutical company’s stock worth $4,649,000 after purchasing an additional 155,559 shares during the last quarter. Kornitzer Capital Management Inc. KS lifted its holdings in shares of Adamas Pharmaceuticals by 81.9% in the 2nd quarter. Kornitzer Capital Management Inc. KS now owns 318,890 shares of the specialty pharmaceutical company’s stock worth $8,237,000 after purchasing an additional 143,535 shares during the last quarter. Deltec Asset Management LLC lifted its holdings in shares of Adamas Pharmaceuticals by 63.3% in the 2nd quarter. Deltec Asset Management LLC now owns 359,796 shares of the specialty pharmaceutical company’s stock worth $9,294,000 after purchasing an additional 139,500 shares during the last quarter. Finally, Lord Abbett & CO. LLC bought a new stake in shares of Adamas Pharmaceuticals in the 1st quarter worth approximately $3,329,000. 95.11% of the stock is currently owned by institutional investors and hedge funds.
Shares of Adamas Pharmaceuticals stock opened at $17.85 on Friday. The company has a debt-to-equity ratio of 0.78, a quick ratio of 9.74 and a current ratio of 9.92. Adamas Pharmaceuticals Inc has a 1-year low of $16.07 and a 1-year high of $44.00.
Several brokerages recently issued reports on ADMS. BidaskClub raised Adamas Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Tuesday, July 17th. HC Wainwright began coverage on Adamas Pharmaceuticals in a report on Monday, July 16th. They issued a “buy” rating and a $45.00 price target on the stock. ValuEngine downgraded Adamas Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, August 28th. Mizuho reissued a “buy” rating and issued a $75.00 price target on shares of Adamas Pharmaceuticals in a report on Friday, August 17th. Finally, Bank of America downgraded Adamas Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price target for the stock from $36.00 to $25.00 in a report on Friday, October 5th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and eleven have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $44.78.
In other Adamas Pharmaceuticals news, CFO Alfred G. Merriweather sold 1,665 shares of Adamas Pharmaceuticals stock in a transaction on Friday, September 21st. The stock was sold at an average price of $19.18, for a total transaction of $31,934.70. Following the sale, the chief financial officer now owns 25,460 shares of the company’s stock, valued at approximately $488,322.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 24.60% of the stock is owned by insiders.
Adamas Pharmaceuticals Company Profile
Adamas Pharmaceuticals, Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. Its partnered approved/commercial products include Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer's disease.
Recommended Story: What Is An Exchange-Traded Fund (ETF)?
Want to see what other hedge funds are holding ADMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Adamas Pharmaceuticals Inc (NASDAQ:ADMS).
Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.